Floatz logo

Berzosertib

Exocrine Pancreatic Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

100 Active assets in the Exocrine Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
OXALIPLATIN
OHSU Knight Cancer Institute
Phase 2/3BBB
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
Vismodegib
OHSU Knight Cancer Institute
Phase 2BB
Capecitabine
Zhejiang University
Phase 2BB

View all 50 →

Same molecule, other indications

Berzosertib is also rated in:

small cell lung carcinomaActive
BBB
Indicative · Phase 2
73 / 100
View asset →
small cell carcinomaActive
BB
Indicative · Phase 2
64 / 100
View asset →
fallopian tube carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →